Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biological Chemistry
Gates Foundation Backs mRNA Vaccines
by Rick Mullin
March 16, 2015
| A version of this story appeared in
Volume 93, Issue 11
The Bill & Melinda Gates Foundation has invested $52 million in CureVac, a German company specializing in messenger RNA (mRNA)-based vaccines. The investment will fund the construction of an industrial-scale vaccine manufacturing facility meeting FDA standards. The foundation will provide separate funding for the development of prophylactic vaccines based on CureVac’s mRNA platform for diseases that affect the developing world. CureVac’s technology uses natural and chemically modified mRNA as a data carrier to instruct the human body on producing its own proteins capable of fighting disease.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter